Baebies received 510(k) clearance and a CLIA waiver for a triplex respiratory test running on its Finder point-of-care system, pairing molecular detection with other clinical chemistry/coagulation functions. The cleared assay distinguishes influenza A, influenza B, and SARS-CoV-2 in respiratory samples, and uses ultra-rapid qPCR rather than endpoint PCR. The company framed the clearance as a milestone because it combines molecular testing and cleared non-molecular modalities on a single multifunctional POC instrument, which has been described as a capability gap across the market. Baebies said Finder supports higher multiplexing potential and has demonstrated multiplexing of 48 targets so far, using droplet shuttling across cartridge temperature and detection zones. The engineering approach is aimed at rapid thermal cycling within small, business-card-sized cartridges. For biotech diagnostics stakeholders, the key watch item is whether multi-modality POC systems can drive broader adoption by reducing visit time and streamlining workflows in primary care, urgent care, and certain outpatient settings.